Update on Hofseth BioCare ASA's Offering Status
Hofseth BioCare ASA, recognized in the biotech industry, has recently made significant announcements regarding its subsequent offering. This offering aimed to raise approximately NOK 30,000,000 through the sale of new ordinary shares designated as Offer Shares at a subscription price of NOK 1.80 each. However, recent developments have led to a change in status.
Details of the Private Placement
Previously, the Company successfully placed new ordinary shares for gross proceeds totaling about NOK 158 million. Yet, it is crucial to highlight that the completion of this Private Placement is still pending receipt of all share deposits. This delay is preventing the registration of the corresponding share capital increase with the Norwegian Register of Business Enterprises.
Implication of the Delay
The Board of Directors at Hofseth BioCare, in light of the ongoing situation, has deemed it unsuitable to complete the Subsequent Offering. Factors such as the current share price level and the wait for all deposits influenced this decision. The cancellation of the Subsequent Offering will mean that all the subscription amounts paid for the Offer Shares will be refunded to the subscribers.
Future Steps for Subscribers
Subscribers wishing to uphold their interest in acquiring Offer Shares need to ensure they reach out to the Company by a specified deadline. Any subscribers who do not take action to maintain their subscription will find their involvement canceled shortly thereafter.
Contact for Subscribers
Any investor or subscriber seeking further information or wishing to take appropriate action can connect with the Company via email.
Company Communication and Investor Relations
The Company assures that updated information regarding the completion of the Private Placement will be communicated in due time. Effective communication remains a priority, and stakeholders can anticipate further clarifications.
Executive Contact Information
For more details, Jon Olav Ødegård, CEO of Hofseth BioCare can be reached directly. He remains the point of contact for any investor inquiries:
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no
Conclusion and Key Takeaways
In summary, while Hofseth BioCare ASA is facing challenges with its Subsequent Offering, the proactive measures during this transitional phase signify the Company's commitment to its investors. Moving forward, a focus on transparent communication will guide stakeholders through this evolving landscape.
Frequently Asked Questions
What led to the cancellation of the Subsequent Offering?
The cancellation was primarily due to delays in completing the Private Placement, which made it unfeasible for the Board of Directors to proceed with the Subsequent Offering.
How much funding was sought through the Subsequent Offering?
The Subsequent Offering aimed to raise approximately NOK 30,000,000 through the issuance of new ordinary shares.
When can subscribers expect refunds for their subscriptions?
Subscribers will receive refunds for their subscriptions as a result of the cancellation of the Subsequent Offering.
Who should subscribers contact for more information?
Subscribers can contact Jon Olav Ødegård, CEO, for further inquiries regarding their subscription status.
How does this situation impact the Company's future fundraising efforts?
The ongoing management of investor communications and careful planning will be critical as Hofseth BioCare navigates through this financial re-strategizing phase.
